Deferoxamine Mesylate for injection — Class III drug recall D-0001-2018
Terminated recall by Pfizer Inc., reported 2017-10-11, distributed nationwide. CGMP Deviations: Firm failed to control impurity for color change at the API stage.
| Recall number | D-0001-2018 |
|---|---|
| Product type | Drug |
| Classification | Class III |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Pfizer Inc., New York, NY, United States |
| Recall initiated | 2017-07-12 |
| Classified | 2017-10-03 |
| Reported by FDA | 2017-10-11 |
| Terminated | 2020-07-16 |
| Distributed | Nationwide (US) |
| Quantity | 32,276 |
| Reason classes | cgmp, specification failure |
| NDC | 00406-2336-10 |
| Lot numbers | 51275DD |
| Expiration dates | 2017-09-01 |
Product
Deferoxamine Mesylate for injection, USP, Single-use Vial, 500 mg/vial, 10 mL vial. Intravenous, Intramuscular, Subcutaneous Use, Rx Only, Hospira, Inc., Lake Forest IL USA, NDC 0406-2336-10.
Reason for recall
CGMP Deviations: Firm failed to control impurity for color change at the API stage.
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0001-2018. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.